The adoption of the roadmap concept, with testing of HBV DNA at week 24, might further minimize resistance. In summary, the study by

selleckchem Liu and colleagues has provided further evidence that off-treatment virological response is not durable, even with adherence to strict cessation criteria. For both HBeAg-positive and -negative patients, the ideal treatment end-points in the era of potent antiviral therapy with low resistance should be the seroclearance of HBsAg. “
“Pancreatic ductal adenocarcinoma represents the commonest type of pancreatic exocrine neoplasm.[1] Early diagnosis of pancreatic cancer is desirable but challenging. Despite improvement in imaging technology, most cases of pancreatic cancers are diagnosed at a late stage, which often precludes surgical resection.[1, 2] Prognosis of advanced pancreatic cancer remains poor, with a 5-year survival rate being less than 10%.[2] Epidemiologically, pancreatic cancer has been thought to affect more people in the Western countries. Although traditionally low incidence rates of pancreatic cancer have been reported in most Asian countries, recent epidemiological

data have shown that the pancreatic cancer incidence has increased over the years in Japan and South Korea, with rates approaching https://www.selleckchem.com/products/abc294640.html that of the Western world.[3] In addition, the pancreatic cancer related mortality in these two Asian countries also approximates that in the United States and Europe.[3] In this issue of the Journal, Kongkam et al. reviewed the epidemiology of pancreatic cancer in Asia and the use of endoscopic ultrasound (EUS) in the evaluation of pancreatic cancer.[4] While the incidence of pancreatic cancer varies in different Asian countries, the authors hope to achieve early detection

of this dreaded malignancy by the use of EUS. In this article, the authors reviewed the fundamental roles of EUS in detection, staging, and tissue acquisition by fine needle aspiration (FNA) of suspected pancreatic cancer. The potential benefits of newer technologies such as contrast harmonic EUS (CH-EUS) and EUS elastography in differentiating pancreatic cancer from other pancreatic neoplasms Immune system were also discussed. Although noninvasive cross-sectional imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are often the first step in the evaluation of suspected pancreatic neoplasm, small pancreatic lesions that are not observed initially on CT or MRI but are eventually picked up by EUS are not uncommon. In studies comparing EUS with multi-detector CT, EUS is shown to have a higher detection rate for small pancreatic masses.[5-7] Accurate preoperative imaging and staging are vital to identifying potentially resectable pancreatic cancers. However, these lesions are often more difficult to detect due to their relatively smaller size.